Mark S. Shearman is CSO & VP at Editas Medicine, Inc. (EDIT). They have made 4 open-market trades across 2 companies since 2016, most recently 2023-02-13.
CIK 0001643799
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $27K since 2016, against 3 sales. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.